DC260126

DC260126 is a potent antagonist of GPR40 (FFAR1) . DC260126 dose-dependently inhibits GPR40-mediated Ca2+ elevations stimulated by linoleic acid, oleic acid, palmitoleic acid and lauric acid (IC50: 6.28, 5.96, 7.07, 4.58 μM, respectively) [1]. DC260126 could protect MIN6 β cells from palmitate-induced ER stress and apoptosis[2].

Product Specifications

CAS Number

[346692-04-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Free Fatty Acid Receptor

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/DC260126.html

Concentration

10mM

Purity

99.74

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=S(C1=CC=C(F)C=C1)(NC2=CC=C(CCCC)C=C2)=O

Molecular Formula

C16H18FNO2S

Molecular Weight

307.38

Precautions

H302, H315, H319, H335

References & Citations

[1]Hu H, et al. A novel class of antagonists for the FFAs receptor GPR40. Biochem Biophys Res Commun. 2009;390 (3) :557-563.|[2]Wu J, et al. Inhibition of GPR40 protects MIN6 β cells from palmitate-induced ER stress and apoptosis [published correction appears in J Cell Biochem. 2013 May;114 (5) :1216]. J Cell Biochem. 2012;113 (4) :1152-1158.